혈전 제거 디바이스 시장 : 시스템 유형, 디바이스 구성 요소, 최종 사용자, 임상 용도별 - 세계 시장 예측(2026-2032년)

The Thrombectomy Devices Market is projected to grow by USD 5.52 billion at a CAGR of 7.81% by 2032.

Thrombectomy Devices Market Executive Summary

Thrombectomy devices are central to modern acute ischemic stroke care because they can physically remove large-vessel occlusions and restore cerebral blood flow when used in the right patient at the right time. Evidence from randomized trials and pooled analyses has established endovascular thrombectomy as standard of care for eligible anterior-circulation large-vessel occlusion, with guideline-supported treatment windows extending to 24 hours in selected patients based on advanced imaging.

The thrombectomy devices landscape is shaped by rising stroke burden, expanding comprehensive stroke center networks, improvements in stent retrievers and aspiration catheters, and growing use of perfusion imaging to identify salvageable brain tissue. Device manufacturers, hospitals, and health systems are competing on speed, reperfusion quality, safety, and workflow integration rather than device mechanics alone.

Transformative Shifts in the Thrombectomy Landscape

The thrombectomy devices landscape is shifting from a device-only market to an integrated stroke systems market. Hospitals increasingly evaluate thrombectomy platforms alongside neuroimaging, transfer protocols, stroke team activation, anesthesia pathways, and post-procedure outcome tracking, because door-to-puncture and reperfusion times directly influence disability outcomes.

Technology is also moving toward larger-bore aspiration systems, improved catheter trackability, combined stent retriever-aspiration techniques, and device designs that support first-pass effect. At the same time, reimbursement pressure and value-based care are pushing suppliers to demonstrate measurable improvements in workflow efficiency, recanalization performance, complication reduction, and total episode-of-care economics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative effect across the thrombectomy pathway by accelerating large-vessel occlusion detection, supporting perfusion assessment, prioritizing emergency notifications, and coordinating transfers between primary stroke centers and thrombectomy-capable hospitals. Regulated AI stroke imaging tools have been adopted by many stroke networks to reduce diagnostic delays, standardize triage, and help clinicians identify patients who may benefit from endovascular thrombectomy.

AI does not replace clinical judgment, but it improves the consistency of time-critical decisions. The strongest near-term opportunity is the integration of AI alerts, imaging review, electronic health records, cath lab readiness, ambulance coordination, and outcomes registries into a single operational workflow that helps teams identify eligible patients faster and measure real-world performance more reliably.

Key Regional Insights: Asia-Pacific, North America, Europe, and Emerging Regions

North America remains a leading region for thrombectomy devices due to mature stroke center certification, strong neurointerventional capacity, broad adoption of computed tomography angiography and perfusion imaging, and established clinical pathways for large-vessel occlusion stroke. Europe shows sustained demand through national and regional stroke networks, guideline-aligned care pathways, and high use of aspiration and stent retriever technologies, although access can vary by country, reimbursement structure, and hospital tier.

Asia-Pacific is the fastest-changing opportunity area as China, India, Japan, South Korea, and Australia expand neurovascular infrastructure, improve emergency stroke triage, and increase adoption of advanced imaging in tertiary hospitals. Latin America is advancing through centers of excellence in Brazil and Mexico, but uneven reimbursement, limited specialist availability outside major cities, and inter-hospital transfer times remain barriers. The Middle East, led by high-investment health systems in Gulf countries, is expanding comprehensive stroke services, digital emergency coordination, and specialist training, while Africa remains underpenetrated due to limited neurointerventional workforce, imaging access, emergency transport coverage, and concentration of thrombectomy services in a small number of urban referral centers.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, demand for thrombectomy devices is rising as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines invest in stroke-ready hospitals, public awareness, and emergency referral systems, though access remains concentrated in urban centers and tertiary institutions. GCC countries are building advanced neurovascular programs through public health investment, specialist recruitment, high-end imaging deployment, and digital emergency care coordination, supporting faster identification and transfer of eligible thrombectomy patients.

The European Union benefits from harmonized clinical guidance, structured procurement systems, cross-border clinical collaboration, and an expanding base of certified stroke centers. BRICS countries represent large-volume clinical opportunity because of high stroke incidence, population scale, and rapid hospital modernization, but reimbursement, device affordability, and specialist availability differ widely across members. G7 markets continue to define clinical benchmarks for thrombectomy workflow, imaging selection, safety reporting, and post-market evidence, while NATO-aligned countries often benefit from emergency response modernization, cross-border training, and resilient medical supply chain planning that can support time-critical stroke intervention.

Key Country Insights Across Major Thrombectomy Markets

The United States leads in thrombectomy procedure volume, technology adoption, clinical research activity, and AI-enabled stroke triage, supported by comprehensive stroke center networks and established reimbursement mechanisms. Canada emphasizes regionalized stroke systems, telestroke, and transfer coordination across large geographies, while Mexico and Brazil are expanding access through large urban hospitals, public-private investment, and growing specialist capabilities in major metropolitan areas.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have mature thrombectomy programs supported by national stroke strategies, established imaging pathways, and trained neurointerventional teams, with Germany and France particularly strong in procedural capacity and specialist infrastructure. Russia has major metropolitan capabilities but uneven regional access caused by geography and variability in hospital resources. China is scaling rapidly through hospital infrastructure expansion and national stroke center development, India is growing from a large unmet-need base with increasing tertiary hospital adoption, Japan and South Korea combine advanced imaging with high device quality expectations and aging-population stroke demand, and Australia benefits from coordinated stroke networks across major cities despite geographic distance and transfer-time challenges.

Actionable Recommendations for Thrombectomy Device Leaders

Industry leaders should prioritize clinical evidence generation, faster workflow integration, and differentiated device performance. The most defensible strategies include demonstrating first-pass reperfusion, lowering distal embolization risk, improving navigation in tortuous anatomy, supporting combined aspiration-stent retriever procedures, and ensuring device compatibility across commonly used access systems.

Commercial teams should align with hospital stroke-network goals by offering physician training, simulation, protocol support, data dashboards, and AI-compatible workflow integration. Manufacturers should also localize market access strategies, strengthen distributor education in emerging regions, support regional centers of excellence, and build post-market evidence that connects device use with functional outcomes, length of stay, complication rates, and cost efficiency.

Research Methodology

This executive summary is developed using a structured secondary research approach that synthesizes guideline-based stroke care evidence, peer-reviewed thrombectomy trial data, regulatory signals, hospital adoption patterns, and regional health system indicators. Core evidence sources include published clinical trials, stroke association guidelines, public regulatory databases, national stroke care frameworks, hospital certification criteria, and reputable health statistics from national and international authorities.

Insights are validated through triangulation across clinical, commercial, regulatory, and policy sources. The methodology emphasizes verified market drivers, technology adoption signals, regional access dynamics, care pathway maturity, and measurable workflow factors such as imaging-to-puncture speed, reperfusion quality, complication reduction, and functional outcome tracking rather than unsupported growth claims.

Conclusion

The thrombectomy devices market is entering a more integrated phase in which device innovation, AI-enabled triage, stroke network maturity, procedural training, and evidence-based reimbursement determine competitive advantage. Demand is supported by the global burden of ischemic stroke and by strong clinical evidence showing that timely thrombectomy improves outcomes in eligible large-vessel occlusion patients.

Organizations that combine high-performing thrombectomy devices with workflow tools, clinical education, and region-specific access strategies will be best positioned to improve adoption while advancing patient outcomes. The next phase of competition will reward measurable speed, safety, reperfusion quality, and real-world value across the full acute stroke care pathway.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Thrombectomy Devices Market, by System Type

• 7.1. Ultrasound-assisted Thrombolysis
• 7.2. Rotational Embolectomy
• 7.3. Thrombus Fragmentation
• 7.4. Rheolytic Embolectomy
• 7.5. Aspiration Thrombectomy

8. Thrombectomy Devices Market, by Device Component

• 8.1. Catheters
• 8.2. Access & Delivery Tools
• 8.3. Consumables & Procedure Kits
• 8.4. Ancillary / Support Devices

9. Thrombectomy Devices Market, by End User

• 9.1. Research & Academic Institutions
• 9.2. Ambulatory Surgical Centers
• 9.3. Hospitals
• 9.4. Specialty Clinics

10. Thrombectomy Devices Market, by Clinical Application

• 10.1. Peripheral / Venous
  • 10.1.1. Renal / Mesenteric Thrombosis
  • 10.1.2. Pulmonary Embolism (PE)
  • 10.1.3. Deep Vein Thrombosis (DVT)
• 10.2. Neurovascular
  • 10.2.1. Cerebral Venous Thrombosis
  • 10.2.2. Acute Ischemic Stroke
• 10.3. Cardiovascular
  • 10.3.1. Peripheral Arterial Thrombosis
  • 10.3.2. Coronary Artery Thrombosis

11. Thrombectomy Devices Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Thrombectomy Devices Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Thrombectomy Devices Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. Acandis GmbH
• 15.3. Anaconda Biomed
• 15.4. AngioDynamics, Inc.
• 15.5. Becton, Dickinson and Company
• 15.6. Boston Scientific Corporation
• 15.7. Cardinal Health, Inc.
• 15.8. Control Medical Technology, LLC
• 15.9. Cook Group Incorporated
• 15.10. Endocor GmbH
• 15.11. Inquis Medical
• 15.12. Johnson & Johnson Services, Inc.
• 15.13. Kaneka Corporation
• 15.14. Koninklijke Philips N.V.
• 15.15. LeMaitre Vascular, Inc.
• 15.16. Medico's Hirata Inc.
• 15.17. Medtronic plc
• 15.18. Meril Life Sciences Pvt. Ltd.
• 15.19. Merit Medical Systems, Inc.
• 15.20. NeuroVasc Technologies Inc.
• 15.21. Nipro Corporation
• 15.22. Penumbra, Inc.
• 15.23. Rapid Medical, Inc.
• 15.24. Stryker Corporation
• 15.25. Surmodics, Inc.
• 15.26. Teleflex Incorporated
• 15.27. Terumo Corporation
• 15.28. Uniphar Medtech
• 15.29. VESALIO
• 15.30. Wallaby Medical Holding, Inc.